Thelansis Forecasts Huge Sickle Cell Disease Market Transformation as Gene Therapies & Oral Disease-Modifiers Reshape the Global Treatment Landscape

New report from Thelansis Knowledge Partners maps the SCD market, epidemiology, competitive landscape, and 10-year forecast (2026-2036) across the US, EU5, Japan, and China, as curative gene therapies and next-generation oral agents redefine standard of care.

EXECUTIVE SUMMARY
Sickle cell disease has moved from a chronically under-resourced condition to one of the most closely watched therapeutic areas in hematology.
The SCD market is entering a genuinely pivotal decade. Two one-time gene therapies, Casgevy and Lyfgenia, have moved curative treatment from concept to clinical reality. while the disease-modifying toolkit is being rebuilt around pyruvate kinase (PK) activators following the withdrawal of earlier polymerization inhibitors and anti-adhesion biologics. Independent market estimates now peg the global SCD treatment opportunity in the mid-single-digit billions in 2026, with double-digit annual growth projected out to 2033-2034 as gene therapy uptake scales and new oral agents reach approval.

Thelansis Knowledge Partners LLP has released its latest report, "Sickle Cell Disease (SCD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 to 2036," offering a comprehensive view of the SCD treatment ecosystem across eight major markets - the US, Germany, France, Italy, Spain, UK, Japan, and China (8MM).

Request a free sample of Thelansis' Sickle Cell Disease (SCD) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/sickle-cell-disease-scd-market-outlook-forecast-2026-to-2036/

KEY EMERGING PLAYERS
• Novo Nordisk has advanced etavopivat, a once-daily PK activator, through the positive Phase 3 HIBISCUS trial, with global regulatory submissions planned for the second half of 2026.
• Vertex Pharmaceuticals / CRISPR Therapeutics continues to expand Casgevy (exagamglogene autotemcel), the first approved CRISPR/Cas9 therapy, with a pediatric (ages 5-11) filing underway and a National Priority Review Voucher supporting a faster review.
• bluebird bio markets Lyfgenia (lovotibeglogene autotemcel), the lentiviral gene-addition therapy, and reports accelerating demand heading into 2026 following its post-approval commercial transition.
• Agios Pharmaceuticals is progressing mitapivat (already approved as Pyrukynd for PK deficiency) through Phase 3 SCD development, with subgroup data pointing to a meaningful hemoglobin-responder population.
• Emerging gene-editing entrants - developers including Editas Medicine (reni-cel) and Beam Therapeutics (BEAM-101) are advancing next-generation base-editing approaches designed to widen access beyond first-generation gene therapy.
• Next-wave in vivo innovators - Tessera Therapeutics and others are pursuing in vivo gene-writing and correction technologies aimed at removing the chemotherapy-based conditioning step that limits current gene therapy access.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Sickle Cell Disease (SCD): https://thelansis.com/reports/sickle-cell-disease-scd-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=scd_mo

KEY CURRENT THERAPIES / STANDARD OF CARE
• Hydroxyurea remains the foundational oral disease-modifying agent, used to elevate fetal hemoglobin (HbF) and reduce vaso-occlusive crisis (VOC) frequency across all 8MM markets.
• L-glutamine (Endari) is used adjunctively to reduce oxidative stress-driven complications in select patient segments.
• Blood transfusion therapy and iron chelation remain in routine use for acute and chronic management, particularly for stroke prevention and severe anemia, and continue to anchor the standard-of-care segment by volume.
• Casgevy and Lyfgenia mark the arrival of one-time, potentially curative treatment for eligible patients aged 12 and older with recurrent VOCs, with pivotal data showing 93.5% and 88% VOC-free rates, respectively, in follow-up.
• Notable contraction: both voxelotor and crizanlizumab have been withdrawn from global markets on safety and efficacy grounds, narrowing the small-molecule and biologic options currently available to physicians and reinforcing the importance of the emerging PK-activator class.

KEY MARKET DRIVERS & TRENDS
• Diagnostic momentum - universal newborn screening and rising diagnostic awareness across the 8MM, including expanding hemoglobinopathy screening programs in China, continue to widen the diagnosed and treated patient pool.
• Access economics under scrutiny - gene therapy list prices of USD 2.2-3.1 million per patient, combined with 4-6 month vein-to-vein treatment timelines and complex chemotherapy-based conditioning, remain the single largest barrier to broader Casgevy and Lyfgenia uptake, even in well-resourced health systems.
• Payer innovation is accelerating - in the US, the CMS Cell and Gene Therapy Access Model now spans 33 states plus Washington, D.C. and Puerto Rico, tying reimbursement to outcomes and offering a template payers elsewhere are watching closely.
• Combination therapy is gaining strategic traction - the daily-oral PK-activator class (mitapivat, etavopivat) is positioned to become the next broad-reach disease-modifying option, potentially used in combination with hydroxyurea ahead of, or alongside, curative gene therapy referral.
• Pipeline depth is expanding fast - with 276+ tracked drug candidates and 780+ patent families filed since 2023 spanning base editing, in vivo delivery, and next-generation HbF inducers, competitive intensity in SCD is rising sharply.
• China market dynamics are increasingly differentiated - China's inclusion in the 8MM scope reflects its growing relevance as a distinct access, pricing, and diagnostic-infrastructure market for hemoglobinopathies, distinct in dynamics from the US and EU5.

Translate these macro drivers into a competitive advantage. Request the Thelansis Sickle Cell Disease (SCD) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/sickle-cell-disease-scd-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=scd_mo

KEY UNMET NEED & KOL EXPECTATIONS
• Reducing treatment burden is the top-ranked need - physicians continue to flag the chemotherapy-based conditioning regimen ahead of gene therapy infusion as the most burdensome part of the patient journey, and KOLs consistently point to in vivo, conditioning-free approaches as the next major inflection point.
• Bridging the eligibility-to-treatment gap - with broad reimbursement often already in place, KOLs note that the vast majority of eligible patients have still not been treated, underscoring a persistent gap between approval, access, and real-world uptake.
• Long-term safety data remains a priority - long-term safety follow-up, particularly around the hematologic malignancy signal associated with lentiviral gene addition, remains a key data readout KOLs are watching to help differentiate therapies for at-risk populations.
• Expectations for label breadth are rising - pediatric label expansion, simplified dosing, and reproductive-health data for PK activators are all cited as near-term priorities to broaden the eligible treatment population.

COMMERCIAL OPPORTUNITY
For biopharma strategy, market access, and commercial teams, the SCD landscape now presents a genuinely layered opportunity: a maturing curative segment anchored by Casgevy and Lyfgenia, an emerging daily-oral disease-modifying segment led by PK activators, and a fast-moving early pipeline exploring in vivo and base-editing approaches.

Thelansis's report is designed to help stakeholders quantify this opportunity with confidence - combining bottom-up, patient-based forecasting validated through top-down sales analysis, country-level epidemiology, KOL and payer interviews, and a fully customizable Excel-based market model spanning the US, EU5, Japan, and China through 2036.

What the report delivers:
• annualized drug-level sales and patient-share projections by country and treatment segment (2026-2036).
•incidence, prevalence, diagnosed and drug-treated population sizing across all 8MM markets.
• competitive profiling of current and emerging therapies, including launch expectations and KOL-validated positioning.
• regulatory and reimbursement landscape analysis by country, including payer-access model insights.
• unmet need and target product profile (TPP) analysis to inform lifecycle and pipeline strategy.

Access the complete Sickle Cell Disease (SCD) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/sickle-cell-disease-scd-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=scd_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.